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eclampsia. Amongst these women, pulmonary oedema (28%), 
intracranial haemorrhage (23%), cerebral oedema resulting in 
coning (9%) and brain death following a hypoxic event (7%) 
were the most frequently recorded final causes of death. 
Although most of these deaths occurred in tertiary and regional 
hospitals, hypertensive deaths still comprised 15% of all 
maternal deaths at Community Health Centres, emphasising 
the importance of correct initial management at all levels of 
care.(6) With regards to the timing of the emergency event 
related to hypertension, 28% (n=191) occurred in the post-
partum period. An important aspect of the Saving Mothers 
report is the attention paid by assessors to avoidable factors, 
missed opportunities and sub-standard care. In the most recent 
report, health worker orientated emergency management 
problems were noted in 42% of hypertensive deaths at Com-
munity Health Centres and District hospitals, 33% at Regional 
hospitals and 17% at Tertiary hospitals.(6) Not only is the 
mortality associated with hypertensive disorders in pregnancy 
high, but these conditions are a frequent source of significant 
morbidity.(8,9) Cases with Severe Acute Maternal Morbidity 
(SAMM) share many characteristics with maternal deaths.(10) 
Therefore understanding and managing SAMM also helps to 
decrease or prevent maternal mortality.
Treatment of hypertension 
during pregnancy
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HYPERTENSION 
DURING 
PREGNANCY
Hypertensive disorders of pregnancy are on the increase 
and remain important causes of maternal and perinatal 
morbidity and mortality. The different classes of hyper-
tension carry different risks but severe hypertension in 
itself remains a medical emergency. Pre-eclampsia is a 
particularly dangerous condition that may progress 
rapidly. During pregnancy mild hypertension without 
end-organ disease does not require treatment until 
levels of 150/100mmHg are reached. Acute severe 
hypertension must be diagnosed and treated expedi-
tiously. The choice of anti-hypertensive agents is limited 
in pregnancy and physicians should choose agents which 
are regarded as safe and which they feel comfortable 
in using. After acute management, oral maintenance 
therapy will be indicated in many cases, although 
delivery is regarded as the only defi nitive treatment for 
pregnancy specifi c conditions such as pre-eclampsia. 
Previous pre-eclampsia is associated with increased 
rates of cardiovascular and metabolic disease in later 
life. This should prompt subsequent lifestyle education 
and intervention.  SAHeart 2014;11:68-74
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INTRODUCTION AND CONTEXT
Hypertension is the most common medical complication 
encountered during pregnancy, complicating 5-15% of all 
pregnancies.(1,2) In a systematic review, Abalos, et al. reported 
upon global and regional estimates of pre-eclampsia and 
eclampsia from 40 countries. Their model gave an estimated 
incidence of 4.6% and 1.4% for pre-eclampsia and eclampsia 
respectively, but they noted wide variations across regions.(3) 
With the increasing prevalence of obesity and diabetes as 
well as the trend to more advanced age at childbirth in many 
countries, the rates of pre-existing (chronic) and pregnancy-
induced hypertensive conditions such as pre-eclampsia seem 
set to rise even further.(4)
The impact of hypertensive diseases on pregnancy is certainly 
important from both maternal and fetal perspectives during 
pregnancy and even thereafter. The maternal mortality asso-
ciated with these conditions remains high in both developed(5) 
and developing countries.(6,7) In South Africa, a legislated con-
fidential enquiry process has facilitated the expert assessment 
of all maternal deaths since 1999. The category of “hyperten-
sive disorders in pregnancy” has consistently remained an 
important primary cause of death. During the 2008-2010 
triennium, hypertensive disorders during pregnancy accounted 
for 14% of all maternal deaths in South Africa. This figure repre-
sented a continued decrease from 19% in 2002-2004 and 16% 
in 2005-2007. In the most recent triennium there were 679 
deaths reported in the hypertension category. Of these, 5% 
were due to chronic hypertension and the rest due to pre-
eclampsia including superimposed and complicated pre-
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From the fetal and neonatal perspective, hypertensive diseases 
of pregnancy remain important causes for delivery of very 
low birthweight babies,(11) preterm births (with the risk of 
intracerebral haemorrhage) and perinatally related losses, that 
are often caused by placental abruption and/or intra-uterine 
growth restriction.(12-14) The perinatal outcomes of the 679 
hypertensive maternal deaths that occurred in the 2008-2010 
triennium in South Africa included 144(21%) stillbirths and 
18(2.7%) neonatal deaths, while 226(33.3%) of the women 
died undelivered.(6)
Anti-hypertensive therapy is used in the acute and non-acute 
clinical scenario. With regards to the non-acute management 
of the hypertensive diseases of pregnancy, Rubin, in 1986, 
noted a shift away from non-pharmacological management 
regimens, such as bed rest or early delivery, towards the 
introduction of anti-hypertensive agents with a view to useful 
prolongation of pregnancy.(15) Clinicians using anti-hyperten-
sive agents during pregnancy have to balance both the benefits 
and the risks of such therapy while considering maternal and 
fetal interests. Although a wide variety of agents have been 
used, few have been subject to controlled clinical trials, due to 
concerns harboured by health research ethics committees and 
pharmaceutical companies.(16) The result is that many medi-
cations are prescribed off-label in doses and frequencies 
extrapolated from research in non-pregnant subjects with a 
very different physiology. This problem is particularly applicable 
to anti-hypertensive agents and remains an ethical conundrum. 
PHYSIOLOGY
Several important physiological changes occur during normal 
and even complicated pregnancies. It is well known that blood 
pressure is directly proportional to systemic vascular resistance 
and cardiac output. Starting early in the first trimester and 
peaking around the 28th week of gestation, the plasma and 
red cell volumes increase by 40% and 25% respectively. The 
greater increment in plasma volume gives rise to the physi-
ologic anaemia of pregnancy. Cardiac output increases by 40% 
during pregnancy and a further 20% during labour. Apart from 
the plasma volume expansion, there is vasodilatation leading to 
a fall in blood pressure during the second trimester of preg-
nancy. This is due to several factors that include vascular 
refractoriness to angiotensin II, as well as increased production 
of endothelial prostacyclin and nitric oxide.(17) The nadir in 
systolic and diastolic pressure is reached at about 22-24 
weeks’ gestation. Thereafter there is a steady rise to pre-
pregnant levels at term. Immediately after delivery, blood 
pressure usually falls and then rises again up to the third or 
fourth day postpartum. The physiological lowering of blood 
pressure in the second trimester may obscure the diagnosis of 
mild chronic hypertension in women without the benefit of 
pre-pregnancy check-ups and who only book for antenatal 
care in the second trimester. When blood pressure remains 
elevated beyond 12 weeks after delivery, the diagnosis of 
chronic hypertension is confirmed.(18) 
CLASSIFICATION 
There are several classification frameworks for hyperten-
sion in pregnancy, some being more complex than others. 
Steegers, et al. have summarised the main differences between 
classifications as: inclusion of non-proteinuric pre-eclampsia; 
differentiation between research and clinical definitions; the 
acceptance of early pre-eclampsia as severe; the definition of 
severe pre-eclampsia and the importance of white-coat 
hypertension.(19) The classification of hypertension in pregnancy 
of the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) is in the final stages of review but key 
aspects of their current classification are shown in Table I.
While most classifications use fixed thresholds it is still recom-
mended that a pregnant woman with a rise in sBP ≥30mmHg 
or dBP ≥15mmHg should be carefully monitored.(17) As seen 
in Table I, hypertension in pregnancy can be broadly divided 
into conditions of pre-existing hypertension, pregnancy-induced 
hypertension (gestational hypertension) and pre-eclampsia 
that manifest clinically after 20 weeks’ gestation. Some women 
will not have been diagnosed with chronic hypertension but 
TABLE 1: Key aspects from the classification and diagnosis of 
the hypertensive disorders of pregnancy by the International 
Society for the Study of Hypertension in Pregnancy (ISSHP).(20)
Defi nition of hypertension in pregnancy
A systolic blood pressure (sBP) ≥140mmHg and or a diastolic (dBP) 
≥90mmHg (K5) respectively.
Classifi cation
Four categories: pre-eclampsia, gestational hypertension, chronic hyper-
tension (essential and secondary), and pre-eclampsia superimposed on 
chronic hypertension.  The defi nitions are listed:
Pre-eclampsia:  The clinical diagnosis is as follows:
•  De novo hypertension after gestational week 20, and new onset of 
one or more of the following
•  Proteinuria (>300mg/day or a spot urine protein/creatinine ratio 
>30mg/mmol)
• Renal insuffi ciency (creatinine >90μmol/L or oliguria)
•  Liver disease (raised transaminases and/or severe right upper 
quadrant or epigastric pain)
•  Neurological problems:  convulsions (eclampsia), hyperrefl exia with 
clonus, severe headaches with hyperrefl exia, persistent visual 
disturbances (scotoma)
•  Haematological disturbances: thrombocytopenia, disseminated 
intravascular coagulation, haemolysis
•  Fetal growth restriction.
Normalisation of blood pressure within 3 months postpartum.
Gestational hypertension:  De novo hypertension alone, appearing 
after gestational week 20.
Chronic hypertension:  Presence or history of hypertension precon-
ception or in the fi rst half of pregnancy.  Considered “essential” if there 
is no underlying cause or “secondary” if associated with defi nitive 
etiology.
Pre-eclampsia superimposed on chronic hypertension:  Development 
of new signs and/or symptoms associated with pre-eclampsia after 
gestational week 20, as above, in a woman with chronic hypertension.
if hypertension is noted before 20 weeks’ gestation, it is likely 
to be a pre-existing problem. In such cases secondary causes 
e.g. renal, cardiac and endocrine should be excluded before a 
diagnosis of essential hypertension is made. Women with 
chronic hypertension are at increased risk of developing super-
imposed pre-eclampsia. Pre-eclampsia is a pregnancy specific 
and particularly dangerous condition with multifactorial etiology 
that is generally characterised by new onset hypertension and 
proteinuria after 20 weeks’ gestation. Pre-eclampsia may be 
complicated by eclampsia (grand mal convulsions), blindness, 
pulmonary oedema, haemolysis, elevated liver enzymes and low 
platelets (HELLP) syndrome, renal failure, placental abruption, 
intra-uterine growth restriction (IUGR) or intra-uterine death 
(IUD) of the fetus. A detailed discussion of pre-eclampsia is 
however beyond the scope of this article. Apart from the 
problems of pre-eclampsia, any form of severe hypertension is 
dangerous due to the association with stroke, end-organ 
damage and placental abruption.(17,21) 
DIAGNOSING HYPERTENSION AND 
TREATMENT GOALS
The Millennium Development Goal number 5 requires a spe-
cific reduction of maternal mortality by 2015. When one 
considers the number of hypertensive deaths occurring 
annually in South Africa, it is clear that the identification of 
hypertension during pregnancy as well as treatment towards 
the prevention and management of hypertensive crises will 
help towards achieving this laudable goal. The implementation 
of clinical guidelines for treatment and referral of pregnant 
women with hypertension has been shown to reduce maternal 
and perinatal risk.(22) 
General antenatal care (history, checking blood pressure and 
urine) is largely directed toward the screening and detection of 
hypertension and pre-eclampsia which may be asymptomatic in 
the early stages. Blood pressure should be measured as it is 
done outside of pregnancy with the patient at rest, sitting 
upright, arms supported and the cuff at the level of her heart. 
When measured in the recumbent position, the patient should 
lie on her side, again with the cuff at the level of her heart. 
Korotkoff V sounds should be used to define diastolic blood 
pressure. Obesity is a problem and “large” cuffs should be 
used when the circumference of the upper arm is ≥33cm. 
Another matter to consider is the device used to measure 
blood pressure. The mercury sphygmomanometer has been 
the gold standard but has been removed from many hospitals 
and clinics due to safety concerns. The replacement devices 
are generally aneroid and automated machines, but only a few 
of the automated blood pressure measuring devices on the 
market have been validated for use in pregnancy. The lower 
threshold for diagnosing hypertension is generally agreed upon 
(see Table I) but the definition of severe systolic hypertension 
(160mmHg or 170mmHg) is still debated due to concerns 
about lethal maternal stroke.(19,21) At Tygerberg Academic 
Hospital, severe hypertension in pregnancy is defined as systolic 
blood pressure (sBP) ≥160mmHg or diastolic blood pressure 
(dBP) ≥110mmHg. Non-severe hypertension is defined as sBP 
140-159mmHg and dBP 90-109mmHg. Parenteral antihyper-
tensive therapy may be necessary to control acute severe 
hypertension but this can be followed by oral maintenance 
therapy.
There is currently no universally accepted standard of care 
although there is broad agreement on the principles of 
assessment, surveillance, management of severe systolic and 
diastolic blood pressures, prevention and treatment of 
eclampsia and avoidance of aggressive rehydration in pre-
eclampsia. In contrast to the non-pregnant scenario, therapy 
for moderate hypertension in pregnancy or pre-eclampsia is 
controversial. This is because women with mild, uncomplicated 
hypertension without end-organ involvement are at lower risk 
of adverse outcomes over the “short period” that pregnancy 
represents.(23) Due to the mid-trimester fall in blood pressure, 
it may be appropriate to stop anti-hypertensive medication in 
uncomplicated pre-existing hypertension, only re-instating it if 
required. Many physicians will still treat non-severe hyperten-
sion in pregnancy in order to reduce the risk of severe 
hypertension and maternal end-organ damage when the blood 
pressure rises above 150/100mmHg, but this has not been 
shown to decrease super-imposed pre-eclampsia.(1,2,24) Systolic 
blood pressure is now regarded as the strongest predictor of 
maternal end-organ damage.(21) With prolonged treatment of 
non-severe hypertension, fetal growth restriction due to pla-
cental hypoperfusion remains a concern, hence the importance 
of fetal surveillance. A Cochrane review of 46 trials, including 
4 282 women, concluded that it remains unclear whether 
antihypertensive drug therapy for mild/moderate hypertension 
in pregnancy is worthwhile.(25)
While therapy for moderate hypertension or pre-eclampsia is 
controversial, it is well accepted in the severe form as severe 
hypertension is associated with more adverse outcomes.(18) 
However, because the placenta functions as a low resistance 
shunt without autoregulation, lowering the blood pressure 
too rapidly or too far is detrimental to the fetus. In the acute 
phase, the aim is an initial reduction of 25% in the first hour, 
followed by further reduction over hours to values below 
160/110mmHg.(18) Thereafter, the target range is 140-155sBP/ 
90-105dBP. A summary of the treatment thresholds and tar-
gets of 5 societies is provided by Vest and Cho.(1) In severe 
hypertension or severe pre-eclampsia the primary purpose of 
therapy is not to change the course of the illness but to pre-
vent cerebral haemorrhage and hypertensive encephalopathy. 
Thus the initial focus for the benefit of therapy is directed 
towards the safety of the mother. It is now known that the fetus 
too can benefit from such therapy when it allows the careful 
continuation of pregnancy remote from term. Regarding severe 
pre-eclampsia, 2 randomised controlled trials have shown that 
expectant management of early onset, severe pre-eclampsia is 
of benefit to premature fetuses.(26,27) These and other studies 
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have shown that perinatal outcome can be directly linked to 
gestation at delivery.(28) Very preterm delivery is associated with 
the significant risks of pulmonary immaturity and the develop-
ment of neurocognitive compromise. The administration of 
betamethasone to enhance fetal pulmonary maturity and 
decrease fetal intraventricular haemorrhage and necrotising 
enterocolitis, together with a short but significant prolongation 
of pregnancy, can greatly improve the neonatal outcome. Due 
to the fact that approximately 2 weeks of gestation can be 
gained by expectant management, oral rather than parenteral 
therapy is the appropriate choice for this longer period of 
therapy. When anti-hypertensive medications are used to 
control blood pressure and postpone delivery in pre-eclampsia 
with the goal of improving fetal outcome, this is only a palliative 
step and the disease process itself is not modified. The timing of 
delivery and balancing of the maternal and fetal risks remains a 
critical decision.
The care of pregnant women with hypertension does not end 
with delivery. Hypertension caused by pre-eclampsia usually 
resolves within a few days of delivery and returns to baseline 
by 12 weeks postpartum.(1) During the post-partum period 
many women will require ongoing control of hypertension 
with oral agents. Labetalol, nifedipine, enalapril and captopril 
are safe during lactation but other ACE inhibitors and angio-
tensin receptor blockers should not be prescribed.(29) For 
women who entered pregnancy with normal blood pressure it 
is generally recommended to discontinue antihypertensive 
medications 3-4 weeks after delivery and then to observe blood 
pressure at regular intervals for one month and then yearly 
thereafter.(1) 
Recently, compelling evidence associating hypertensive dis-
orders in pregnancy with cardiovascular risk factors, has been 
presented.(30) A very large study from Norway(31) together with 
others from around the world offer plausible evidence that 
women who experienced pregnancy-related hypertension are 
at elevated risk for hypertension and metabolic disorders such 
as non-insulin dependent diabetes mellitus later in life.(30,32) 
Although it is still uncertain whether the associations between 
pregnancy hypertension and subsequent chronic disease are 
due to common pre-existing conditions or by the direct effect 
of the complication during pregnancy, the former hypothesis 
is currently thought to be more likely.(4) This debate should 
however not delay the implementation of simple measures 
aimed at improving long-term outcomes such as smoking 
cessation, diet, management of obesity, exercise programmes 
and regular checking of blood pressure, lipid and glucose 
profiles. Cardiologists in particular should take note of these 
associations.
ANTI-HYPERTENSIVE AGENTS
The management of pregnant women with hypertension is 
based on the following principles:
 ■ Exclude secondary causes of hypertension when hyper-
tension presents before 20 weeks’ gestation.
 ■ Exclude or confirm pre-eclampsia after 20 weeks’ gestation.
 ■ Treat the hypertension.
 ■ Fetal surveillance.
 ■ Decide on timing and type of delivery.
In this section only the third principle will receive detailed 
attention but readers are encouraged to read more widely, 
particularly regarding pre-eclampsia. Regardless of the under-
lying pathology, severe hypertension merits treatment in its 
own right, because when the mean arterial pressure rises above 
150 there is loss of cerebral auto-regulation and a risk of 
cerebral haemorrhage. However, in pre-eclampsia cerebral 
complications can occur without very high blood pressure as 
blood pressure does not always correlate with auto-regulation 
functionality.(33) As stated in the introduction there are insuf-
ficient randomised trials to direct the optimal treatment of 
hypertension in pregnancy, thus physicians should use the agent 
with which they feel most comfortable.(34)
Hypertensive emergencies
Therapy for acute severe hypertension is essential. The primary 
purpose of therapy is not to change the course of the illness 
but to prevent cerebral haemorrhage, hypertensive encepha-
lopathy, acute renal or cardiac failure, arrhythmias or placental 
abruption. Although the initial focus on the benefit of therapy is 
directed towards the safety of the mother whose well-being 
takes priority in the acute phase, the fetus too benefits from 
such therapy, particularly when it allows the careful continuation 
of pregnancy remote from term. If the reduction in blood 
pressure is too rapid, this may lead to inadequate uteroplacental 
blood flow. A fast but smooth and controlled reduction is the 
ideal. Careful fetal monitoring to detect fetal distress is required 
but maternal well-being takes priority in the acute phase. 
Women with acute severe hypertension should be stabilised 
and transferred to, or managed in a high-care dependency unit. 
Physicians should be aware that automated oscillometric 
devices may underestimate blood pressure.(35) Women with 
pre-eclampsia and acute severe hypertension have a reduced 
intravascular volume and require pre-treatment with a small 
volume of fluid e.g. 250ml crystalloid fluid before or during 
administration of anti-hypertensive medication.(36) The following 
agents are commonly used. Drug safety classes are shown in 
Table 2. 
 ■ Nifedipine (Class C) 5mg or 10mg (short-acting capsule) 
swallowed. Note: In the pregnant patient the capsule should 
not be bitten or administered sub-lingually. A rapid effect 
on the blood pressure can still be anticipated. It may be 
repeated every 30 minutes as needed. Nifedipine should 
be avoided in women with known atherosclerotic cardio-
vascular disease, a long history of diabetes (>15years) or 
>45years of age due to the risk of sudden cardiac death.(37)
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 ■ Dihydralazine (Class C) Mix one ampoule with 20ml sterile 
water. Administer 2ml (2.5mg) boluses intravenously every 
20 minutes until blood pressure is <160/110mmHg. When 
the patient is ready for transfer, administer 6.25mg intramus-
cularly. It has been associated with more side-effects than 
other rapid-acting agents.(38,39)
 ■ Labetalol (Class C) When maternal tachycardia accom-
panies acute severe hypertension labetalol is a good option. 
A 20mg intravenous bolus followed by 40mg if not effective 
within 10 minutes; then 80mg every 30 minutes to a maxi-
mum total dose of 220mg. It may also be used as a 
continuous infusion.
 ■ Magnesium sulphate (MgSO4) (Class B) This drug is not an 
anti-hypertensive agent but is used for the treatment and 
prevention of eclampsia in the acute scenario. A 4g intra-
venous loading dose over 15 minutes is followed by an 
infusion of 1g/hour. 
The aim here is not to normalise the blood pressure, but rather 
to reduce the pressure to levels associated with a decreased 
risk of vascular accidents. In the acute scenario, the aim is to 
reduce the sBP/dBP to <160/110mmHg while recording the 
blood pressure every five minutes until stable. In a meta-analysis 
investigating treatment for severe hypertension in pregnancy, 
Magee, et al. concluded that hydralazine lacked support as a 
first line agent and that nifedipine and labetalol showed pro-
mise.(38) In 2013 a small randomised controlled trial comparing 
oral nifedipine to intravenous labetalol for hypertensive emer-
gencies in pregnancy showed nifedipine to be superior.(40) 
Following control of severe hypertension, oral maintenance 
therapy should be instituted or increased.
Oral maintenance therapy
The commonly considered agents are briefly discussed below. 
The ideal agent for use during pregnancy should have the 
following characteristics: ease of administration, rapid onset of 
action, controlled lowering of blood pressure, a sustained 
duration of action, maintenance of placental blood flow and 
lack of serious side effects for the mother and fetus. Classes of 
agents may be combined when maximum doses are inade-
quate to achieve the desired blood pressure goals. An increas-
ing body of evidence suggests that maternal hypertensive 
diseases during pregnancy are associated with adverse 
neurocognitive outcomes in children.(41) It is therefore difficult 
to separate the effects of the disease and the therapy but 
evidence suggests that methyldopa, labetalol and nifedipine are 
the safer agents.(41,42)
Methyldopa (Class B), which acts as a false neurotransmitter in 
the central nervous system is widely regarded as the first choice 
agent during pregnancy.  It has no effect on the cardiac output. 
Importantly, it has been prospectively evaluated in randomised 
clinical trials and has been shown to be safe for the mother, 
neonate and infant. Unfortunately methyldopa has only mild 
potency with a low oral bioavailability and a slow onset of 
action. Sedation and depression are both recognised side 
effects when high doses are used. It should therefore be 
avoided in the postpartum period. The typical dosage starts 
with 250mg 8-hourly, increased as necessary to a maximum of 
750mg 8-hourly. When a second agent is needed to control 
maternal blood pressure the patient should be referred to an 
institution with specialist care.
Nifedipine (Class C), is a widely used calcium channel blocking 
agent. The use of nifedipine in pregnancy has been fairly well 
investigated. A number of randomised controlled trials have 
shown nifedipine to be an effective anti-hypertensive agent.(43-45) 
It has been used for acute and maintenance therapy, moderate 
and severe degrees of hypertension and for chronic as well 
as pregnancy induced conditions. A useful attribute of nifedipine 
is that the degree of reduction in blood pressure it produces 
appears to be directly proportional to the pre-treatment 
pressure.(46) It should be noted that with regards to uteropla-
cental perfusion, the normotensive situation differs substantially 
from pre-eclampsia. In normal pregnancies the uterine spiral 
arteries are converted to uteroplacental arteries by tropho-
blast invasion. Thus their muscular components are lost and a 
low-resistance/high-flow system is formed. In pre-eclampsia this 
fails to occur completely and uteroplacental flow is reduced. So, 
while calcium channel blocking agents have little direct effect 
on the normal uteroplacental bed, they may be able to exert 
a direct vasodilatory effect in pre-eclampsia, because of the 
partial preservation of the muscular component of the arteries. 
A study reporting on in-utero exposure to nifedipine and the 
development of children up to the age of 18 months shows 
the agent to be safe.(42)
Other reported benefits of calcium channel blockers include 
their rapid onset of action after oral administration,(40,47) 
inhibition of platelet aggregation,(15) decrease in erythrocyte 
TABLE 2: Drug rating in pregnancy.(17)
A   Controlled studies show no risk
  Adequate, well-controlled studies in pregnant women have failed to 
demonstrate risk to the fetus.
B   No evidence of risk in humans
  Either animal fi ndings show risk (but human fi ndings do not) or, if 
no adequate human studies have been done, animal fi ndings are 
negative.
C Risk cannot be ruled out
  Human studies are lacking and animal studies are either positive for 
fetal risk or lacking as well.  However, potential benefi ts may justify 
the potential risk.
D Positive evidence of risk
  Investigational or post marketing data show risk to fetus.  Never-
theless, potential benefi ts may outweigh the risk.
X Contra-indicated in pregnancy
  Studies in animals or humans, or investigational or post marketing 
reports have shown fetal risk which clearly outweighs any possible 
benefi t to the patient.
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aggregation,(48) improved renal function(49) and increased urinary 
excretion of prostacyclin metabolites.(50) Despite causing vaso-
dilatation, these agents seldom cause a problematic tachycardia. 
Transient facial flushing, headaches and warm sweaty extremi-
ties seem to be the most common side effects. The typical 
dosage starts with 30mg (slow release formulation) daily or 
12-hourly as necessary, to a maximum of 120mg daily.(51) The 
combination of a calcium channel blocker and MgSO4 has been 
shown to be safe.(52)
β-adrenergic blocking agents e.g. atenolol (Class D). The 
mechanism of action involves a reduction in cardiac output, a 
central adrenergic effect and a blockage of renin secretion. 
These agents may cause fetal intra-uterine growth restriction 
(IUGR) and neonatal hypoglycaemia, but may be used in the 
postpartum period. Labetalol (Class C) is a unique adrenoceptor 
antagonist as it has both α-1 and non-selective β-blocking 
effects. It lowers blood pressure without compromising the 
maternal cardiovascular system by producing peripheral vaso-
dilatation. β-blockers should be avoided in patients with asthma 
and congestive heart failure. The dose of oral labetalol begins 
at 200mg 12-hourly, increasing to a maximum of 1 200mg con-
stituted in 2-3 divided doses.
Hydralazine (Class C), acts directly on the vascular wall 
producing vasodilatation. When administered orally the effect is 
weak. 
Diuretics e.g. hydrochlorothiazide (Class B). The use of 
these agents during pregnancy is controversial, largely due to 
the volume depletion associated with pre-eclampsia. Their use 
should be limited to women with early, severe chronic 
hypertension.
Angiotensin converting enzyme (ACE) inhibitors, angiotensin 
receptor blockers and direct renin inhibitors (all Class D), are 
contra-indicated in pregnancy as they have been linked to com-
plications throughout pregnancy including congenital anomalies, 
IUGR, oligohydramnios and perinatal renal failure.(20) Enalapril 
and captopril may be used with safety during lactation.
With oral maintenance therapy the majority of patients are 
controlled on methyldopa, and/or nifedipine. In problematic 
cases labetalol is useful.
CONCLUSION
There is no doubt that clinicians managing pregnant patients 
must have a thorough understanding of the management of 
hypertension. The choice of agents will vary according to the 
clinical situation but each clinical decision must be underpinned 
by knowledge of the agent to be used as well as the risks and 
benefits of such therapy to both the mother and the fetus or 
newborn infant.
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